AstraZeneca Plc has held discussions with U.S.-based Bristol Myers Squibb (BMS) over a potential merger that could create one of the world's largest pharmaceutical companies with a combined market value of nearly $400 billion, according to an exclusive report by the Financial Times, which cited people familiar with the matter.
According to the report, the discussions have taken place in recent months, although they remain at an exploratory stage and may not ultimately lead to a formal transaction. Neither AstraZeneca nor Bristol Myers Squibb has publicly confirmed the talks, and both companies declined to comment when contacted by the Financial Times.
If completed, the transaction would rank among the largest mergers ever in the pharmaceutical industry and create the world's fourth-largest drugmaker by market capitalization. The combined company would significantly strengthen its presence in the U.S. pharmaceutical market while bringing together extensive portfolios in oncology, immunology, cardiovascular diseases, and other specialty medicines.
The report comes as AstraZeneca continues to expand its U.S. footprint and pursue its long-term goal of generating $80 billion in annual revenue by 2030. Industry observers note that acquiring Bristol Myers Squibb could further enhance AstraZeneca's position in the U.S., although the combined business would likely face close antitrust scrutiny because both companies have significant oncology franchises.
Investors React Cautiously
The reports triggered a sharp reaction in financial markets. AstraZeneca's shares fell more than 6% in London trading, while Bristol Myers Squibb shares moved higher, reflecting contrasting investor sentiment toward the proposed tie-up.
Several analysts questioned the strategic rationale for such a large acquisition. They argued that AstraZeneca has consistently delivered strong financial and pipeline performance under Chief Executive Pascal Soriot and may not require a transformational merger. Analysts also raised concerns over potential integration challenges, regulatory hurdles, overlapping oncology assets, and the possibility that the deal could dilute AstraZeneca's near-term growth prospects.
At present, there has been no official announcement, regulatory filing, or press release from either company confirming the merger discussions. The information is based on the Financial Times' exclusive report citing people familiar with the matter.
